You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 27, 2026

Robust Generation of Hepatocyte-like Cells from Human Embryonic Stem Cell Populations
Published on: October 26, 2011
Gustav Holmgren1, Anna-Karin Sjögren2, Isabel Barragan2
1Systems Biology Research Center, School of Bioscience, University of Skövde, Skövde, Sweden (G.H., P.S., J.S.); Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden (G.H.); Department of Discovery Safety, Drug Safety and Metabolism, AstraZeneca R&D, Mölndal, Sweden (A.-K.S.); Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden (I.B., T.B.A., M.I.-S.); Department of Bioscience, Cardiovascular and Metabolic Diseases, AstraZeneca R&D, Mölndal, Sweden (A.S.); NovaHep AB, Gothenburg, Sweden (P.B.); Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D, Mölndal, Sweden (T.B.A.); and Cellectis AB, Gothenburg, Sweden (P.S., P.B., J.E.) Gustav.holmgren@his.se.
Human pluripotent stem cells (hPSC)-derived hepatocytes show promise for long-term drug toxicity testing. These cells demonstrated increased sensitivity to toxic compounds and revealed specific liver damage, improving preclinical models.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: